KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $474.6 million.

  • Jazz Pharmaceuticals' Cash from Operations rose 1902.69% to $474.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 1950.5%. This contributed to the annual value of $1.4 billion for FY2024, which is 2782.96% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Cash from Operations stood at $474.6 million for Q3 2025, which was up 1902.69% from $88.9 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash from Operations peaked at $474.6 million during Q3 2025, and registered a low of $41.7 million during Q2 2021.
  • Its 5-year average for Cash from Operations is $291.1 million, with a median of $303.0 million in 2022.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 7715.58% in 2021, then skyrocketed by 62679.22% in 2022.
  • Jazz Pharmaceuticals' Cash from Operations (Quarter) stood at $177.8 million in 2021, then soared by 92.38% to $342.0 million in 2022, then tumbled by 51.07% to $167.3 million in 2023, then soared by 138.19% to $398.6 million in 2024, then increased by 19.08% to $474.6 million in 2025.
  • Its Cash from Operations was $474.6 million in Q3 2025, compared to $88.9 million in Q2 2025 and $429.8 million in Q1 2025.